A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Advanced or Metastatic Solid Tumors
Latest Information Update: 17 Jun 2025
At a glance
- Drugs BL M05D1 (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors SystImmune
Most Recent Events
- 17 Jun 2025 New trial record